AKTS (Aktis Oncology) Beta: N/A (As of Jun. 26, 2026)


AKTS Aktis Oncology Inc AKTS
9 GF Score
Price $31.15
! 3 Warning Signs
View Full Analysis

What is Aktis Oncology Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-26), Aktis Oncology's Beta is Not available.

Aktis Oncology  (NAS:AKTS) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)

Aktis Oncology Beta Related Terms

Aktis Oncology Beta Historical Data

* Premium members only.

The historical data trend for Aktis Oncology's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aktis Oncology Beta Chart

Aktis Oncology Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Beta
0.00 0.00 0.00 0.00

Aktis Oncology Quarterly Data
Dec22 Dec23 Sep24 Dec24 Mar25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00
AKTS
9GF Score
Aktis Oncology Inc AKTS
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aktis Oncology Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Aktis Oncology Business Description

Address 17 Drydock Avenue, Suite 17-401, Boston, MA, USA, 02210
Aktis Oncology Inc is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company specializes in developing targeted alpha radiopharmaceuticals for solid tumors such as breast, lung, colorectal, bladder, and liver cancers. Its pipeline products include AKY-1189 and AKY-2519, focusing on solid tumors. The company has one operating and reportable segment focused on the research and development of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. The company generates revenue from Collaboration agreement.
9GF Score

Get the complete analysis for AKTS

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$31.15
Price